Endo unit launches generic version of Merck blockbuster
An Endo International operating company this week launched the first generic version Merck ’s multibillion-dollar, cholesterol-lowering medicine Zetia.
North Jersey-based Par Pharmaceuticals, which Endo (NASDAQ: ENDP) acquired last year for $8 billion, is the marketer and distributor of the product in the United States. Endo, based in Dublin, Ireland, has its U.S. headquarters in Malve rn.
Endo eliminates 375 sales jobs
According to data from IMS Health, U.S. sales of Zetia were about $2.6 billion… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 14, 2016 Category: American Health Authors: John George Source Type: news
India Launches First Generic of Merck's Zetia in U.S.
India ' s Glenmark Pharmaceuticals has launched the first and only generic version of Zetia -- Merck ' s cholesterol drug -- in the U.S. market. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 13, 2016 Category: Pharmaceuticals Source Type: news
Glenmark launches generic version of Zetia in US market
"We have launched ezetimibe, the first and only generic version of Zetia (Merck) in the United States for the treatment of high cholesterol," (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 12, 2016 Category: Pharmaceuticals Source Type: news
Liptruzet (Ezetimibe and Atorvastatin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 9, 2016 Category: Drugs & Pharmacology Source Type: news
Zetia (Ezetimibe Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 12, 2016 Category: Drugs & Pharmacology Source Type: news
Farewell to the fasting cholesterol test?
At a recent meeting I offered a visitor lunch which she declined with obvious regret. She was hungry, and it was noon. But she was headed to her annual physical, and eating beforehand would mean returning another morning for a fasting cholesterol level. Most of us can relate to her annoyance, but thankfully this may soon be a thing of the past.
Doctors have traditionally ordered cholesterol tests to be drawn after an overnight fast. But this requirement causes a significant burden on both sides of the health care equation. Most people hate to fast. Skipping meals is particularly difficult for active people, people with dia...
Source: New Harvard Health Information - June 16, 2016 Category: Consumer Health News Authors: Naomi D. L. Fisher, MD Tags: Health Heart Health Prevention Screening Tests and procedures Source Type: news
Merck posts better-than-expected profit, raises forecast
(Reuters) - Merck & Co Inc reported better-than-expected profit in the first quarter, driven by higher sales of its diabetes drug Januvia and heart drug Zetia. (Source: Reuters: Health)
Source: Reuters: Health - May 5, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
New drug 'effective' for those with intolerable statin side effects
Conclusion
The main results of this study relate to the lipid-lowering effects of two alternative non-statin medications. However, it highlights the muscle-related adverse effects that can occur with statins.
The study is carefully designed and has many strengths, including:
a washout period between drugs to remove any residual effects
double-blind design throughout so people didn't know what they were taking
sufficient duration for each phase of the study (10 and 24 weeks) to allow effects to develop
a good sample size – the researchers calculated beforehand how many people would need to be recruite...
Source: NHS News Feed - April 4, 2016 Category: Consumer Health News Tags: Heart/lungs Medication Older people Source Type: news
Trial offers objective evidence of muscle-related side effects with statins
The first major clinical trial to include a blinded, placebo-controlled “statin re-challenge” in patients with a history of muscle-related side effects sheds new light on statin-associated muscle symptoms, according to new research. The trial also demonstrates that monthly self-injection of the relatively new non-statin cholesterol-lowering drug evolocumab reduces levels of low-density lipoprotein, or LDL, cholesterol to a greater extent than ezetimibe, a traditional drug used in statin-intolerant patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 4, 2016 Category: Science Source Type: news
Some People Really Can't Take Statins For High Cholesterol, Scientists Prove
You can't write a story about the lifesaving benefits of the cholesterol-lowering drugs called statins without getting comments like this one, from reader Bill Hayman, on my story yesterday:
I cannot take Crestor or Zetia or any form of statin drug! I can barely walk with any statin drug. My legs become painful and so weak, they feel like rubber. Several years ago, I used Lipitor and had four pancreatic attacks until I stopped the Lipitor.
Or this, from reader James Leedy:
People should be warned of side effects. Doctors should listen to patients . I have taken statins for several years. I had extreme muscle pains all t...
Source: Forbes.com Healthcare News - April 3, 2016 Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association"
Data Simultaneously Presented in Late-Breaking Session at ACC.16
Repatha Compared to Ezetimibe Resulted in Significantly Greater Reduction in LDL-C
THOUSAND OAKS, Calif., April 3, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) trial evaluating Repatha® (evolocumab) in patients with high cholesterol who cannot tolerate statins. The study showed that in patients with reproducible statin intolerance due to muscle-related side effects (MRSE), the use of Repatha compared to ezeti...
Source: Amgen News Release - April 3, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Positive Efficacy And Tolerability Study Of Repatha® (evolocumab) In Statin-Intolerant Patients Published In Journal of the American Medical Association
Data Simultaneously Presented in Late-Breaking Session at ACC.16
Repatha Compared to Ezetimibe Resulted in Significantly Greater Reduction in LDL-C
THOUSAND OAKS, Calif., April 3, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new detailed data from the Phase 3 GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3) trial evaluating Repatha® (evolocumab) in patients with high cholesterol who cannot tolerate statins. The study showed that in patients with reproducible statin intolerance due to muscle-related side effects (MRSE), the use of Repatha compared to ezeti...
Source: Amgen News Release - April 3, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Cholesterol lowering therapies for patients with muscle-related statin intolerance
(The JAMA Network Journals) Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. The study was published online by JAMA, and is being released to coincide with its presentation at the American College of Cardiology's 65th Annual Scientific Session & Expo. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2016 Category: Global & Universal Source Type: news
Statin intolerance objectively identified in patients
(Cleveland Clinic) In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 3, 2016 Category: Global & Universal Source Type: news
Lupus Lipids Improve With Combo Tx (CME/CE)
(MedPage Today) -- Treatment with pravastatin and ezetimibe also benefited endothelial function (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 12, 2016 Category: Primary Care Source Type: news
